Stephens Reiterates Overweight Rating for Actinium Pharmaceuticals (NYSE:ATNM)

Stephens reaffirmed their overweight rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $5.00 target price on the stock.

Several other research firms also recently commented on ATNM. StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Maxim Group decreased their price objective on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a report on Friday, November 15th. Finally, B. Riley downgraded shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $16.00 to $2.00 in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.40.

Actinium Pharmaceuticals Price Performance

NYSE ATNM opened at $1.44 on Tuesday. The stock’s fifty day moving average price is $1.75. Actinium Pharmaceuticals has a 1 year low of $1.33 and a 1 year high of $10.24. The company has a market capitalization of $44.93 million, a price-to-earnings ratio of -1.04 and a beta of 0.14.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Rhumbline Advisers grew its stake in Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after buying an additional 7,525 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Actinium Pharmaceuticals during the second quarter worth about $92,000. Bank of New York Mellon Corp grew its stake in Actinium Pharmaceuticals by 28.3% during the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after buying an additional 19,035 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Actinium Pharmaceuticals during the second quarter worth about $142,000. Finally, Interchange Capital Partners LLC acquired a new stake in Actinium Pharmaceuticals during the third quarter worth about $37,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).